To include your compound in the COVID-19 Resource Center, submit it here.

Reolysin reovirus: ONC began a North American Phase I/II trial in about 38 patients with recurrent malignant glioma.

Oncolytics Biotech Inc. (TSE:ONC; ONCY),

Read the full 56 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE